The financial burden on health systems would drastically increase if new European expert guidelines for cholesterol-lowering treatment were implemented, according to a new simulation study. The findings highlight an urgent need for cost-effectiveness analysis given the current cost of the proposed treatment for very high-risk patients, the researchers say.